Trial Outcomes & Findings for Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness (NCT NCT00393913)

NCT ID: NCT00393913

Last Updated: 2016-08-05

Results Overview

Measured using the Epworth sleepiness scale (ESS). The Epworth sleepiness scale is used in the assessment of daytime sleepiness and measures the general level of sleepiness.The ESS presents the subject with eight situations and asks how likely they are to fall asleep (0= never, 1 =slight chance of dozing, 2= moderate chance of dozing and 3 =high chance of dozing) in these situations. The sum of the 8 answers is used as the score and ranges from 0 (not sleepy) to 24 (extremely sleepy), and a score of greater than 10 is an indication that a person may be excessively sleepy.

Recruitment status

COMPLETED

Target enrollment

144 participants

Primary outcome timeframe

Baseline, CPAP( 4 -6 weeks), Off CPAP ( 2 nights)

Results posted on

2016-08-05

Participant Flow

Normal volunteers and patients with symptoms of sleep apnea evaluated at the NYU sleep disorders center.

Subjects with sleep disorders other than sleep apnea were not included for initial assessment of the effect of sleep apnea severity to daytime function.

Participant milestones

Participant milestones
Measure
CPAP
All participants with sleep apnea will use a CPAP machine for treatment of sleep apnea.
Initial Assessment
STARTED
144
Initial Assessment
COMPLETED
107
Initial Assessment
NOT COMPLETED
37
CPAP
STARTED
100
CPAP
COMPLETED
93
CPAP
NOT COMPLETED
7
CPAP Withdrawal
STARTED
42
CPAP Withdrawal
CPAP Compliance
42
CPAP Withdrawal
COMPLETED
42
CPAP Withdrawal
NOT COMPLETED
0

Reasons for withdrawal

Reasons for withdrawal
Measure
CPAP
All participants with sleep apnea will use a CPAP machine for treatment of sleep apnea.
Initial Assessment
diagnosed with other sleep disorder
21
Initial Assessment
Withdrawal by Subject
16
CPAP
Withdrawal by Subject
3
CPAP
Physician Decision
1
CPAP
TEchnical problem with CPAP
3

Baseline Characteristics

Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sleep Apnea Assessment
n=107 Participants
All participants were assigned to a single Arm (and received the intervention based on whether they had sleep apnea). Participants with sleep apnea used the CPAP machine for 4 to 6 weeks every night and then returned to the sleep laboratory for assessment of daytime function. Those without sleep apnea will have the initial assessment but then will not receive the intervention.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
103 Participants
n=5 Participants
Age, Categorical
>=65 years
4 Participants
n=5 Participants
Age, Continuous
45 years
STANDARD_DEVIATION 12 • n=5 Participants
Sex: Female, Male
Female
38 Participants
n=5 Participants
Sex: Female, Male
Male
69 Participants
n=5 Participants
Region of Enrollment
United States
107 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline, CPAP( 4 -6 weeks), Off CPAP ( 2 nights)

Measured using the Epworth sleepiness scale (ESS). The Epworth sleepiness scale is used in the assessment of daytime sleepiness and measures the general level of sleepiness.The ESS presents the subject with eight situations and asks how likely they are to fall asleep (0= never, 1 =slight chance of dozing, 2= moderate chance of dozing and 3 =high chance of dozing) in these situations. The sum of the 8 answers is used as the score and ranges from 0 (not sleepy) to 24 (extremely sleepy), and a score of greater than 10 is an indication that a person may be excessively sleepy.

Outcome measures

Outcome measures
Measure
Sleep Apnea
n=107 Participants
All participants with obstructive sleep apnea (and no other sleep disorder) and subjects without sleep apnea.
Subjective Sleepiness
Baseline ESS
11.8 units on a scale
Standard Deviation 5.6
Subjective Sleepiness
CPAP ESS
10.2 units on a scale
Standard Deviation 5.0
Subjective Sleepiness
CPAP withdrawal ESS
9.9 units on a scale
Standard Deviation 4.6

PRIMARY outcome

Timeframe: Measured at baseline, on CPAP (4-6 weeks), CPAP withdrawal (2 nights)

Multiple Sleep Latency Test (MSLT) measures the latency to sleep onset in minutes. The shorter the latency to sleep the more sleepy the subject.

Outcome measures

Outcome measures
Measure
Sleep Apnea
n=107 Participants
All participants with obstructive sleep apnea (and no other sleep disorder) and subjects without sleep apnea.
Objective Sleepiness
Sleep Latency-Baseline
6.4 minutes
Standard Deviation 3.7
Objective Sleepiness
Sleep Latency-CPAP
5.9 minutes
Standard Deviation 3.1
Objective Sleepiness
Sleep Latency-CPAP withdrawal
7.8 minutes
Standard Deviation 4.1

PRIMARY outcome

Timeframe: Baseline, CPAP (4-6 weeks), CPAP withdrawal (2 nights)

Population: Per protocol

Vigilance is measured using the psychomotor vigilance task which is a portable reaction time test that is contained in a small, programmable, portable electronic box that requires only a single switch to start. The task consists of responding to a small bright red light stimulus by pressing a response button as soon as the stimulus appears. This stops the stimulus counter and displays the reaction time (RT) in milliseconds for a 2-second period and the task duration is 20 minutes. The subject is instructed to press the button as soon as each stimulus appears in order to keep the reaction time as low as possible. The PVT yields highly informative metrics on the capacity for sustained attention including the frequency of lapses (reaction time \> 500 milliseconds). The higher the number of lapses the greater the impairment. Well rested (non-sleepy) subjects have almost no lapses(\<2) during the 20min test.

Outcome measures

Outcome measures
Measure
Sleep Apnea
n=107 Participants
All participants with obstructive sleep apnea (and no other sleep disorder) and subjects without sleep apnea.
Vigilance
Baseline
5.9 Lapses
Standard Deviation 4.1
Vigilance
CPAP
4.1 Lapses
Standard Deviation 2.6
Vigilance
CPAP withdrawal
6.5 Lapses
Standard Deviation 4.5

Adverse Events

Continuous Positive Pressure Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Indu Ayappa, PhD

NYU School o Medicine

Phone: 2125628437

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place